Investment Analysts’ Recent Ratings Updates for Innoviva (INVA)

Several analysts have recently updated their ratings and price targets for Innoviva (NASDAQ: INVA):

• 11/19/2025 – Innoviva had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Innoviva had its “buy (b-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/7/2025 – Innoviva was upgraded by analysts at Weiss Ratings from a “hold (c)” rating to a “buy (b-)” rating.
• 11/6/2025 – Innoviva was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/6/2025 – Innoviva had its price target raised by analysts at Cantor Fitzgerald from $29.00 to $31.00. They now have an “overweight” rating on the stock.
• 10/25/2025 – Innoviva was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/8/2025 – Innoviva was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 10/8/2025 – Innoviva had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/3/2025 – Innoviva was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 9/30/2025 – Innoviva is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $17.00 price target on the stock.
• 9/30/2025 – Innoviva is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “sell” rating and a $17.00 price target on the stock.
• 9/27/2025 – Innoviva had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.